FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
16 sept. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's officeThis approval is backed by a decade of proven safety...
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
13 sept. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq1,2New subcutaneous (SC)...
Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen
10 sept. 2024 10h00 HE
|
F. Hoffmann-La Roche Ltd
Das innovativste Forschungs- und Entwicklungszentrum der Schweiz unterstreicht Roches langfristige Investitionen in den wissenschaftlichen Fortschritt, um den Bedürfnissen der Patienten gerecht zu...
Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation
10 sept. 2024 10h00 HE
|
F. Hoffmann-La Roche Ltd
Switzerland’s most innovative research and development center underscores Roche’s long-term investment in scientific advancement to meet patient needsThe new center will simplify and increase...
Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
04 sept. 2024 02h00 HE
|
F. Hoffmann-La Roche Ltd
New Phase II data show vast majority of patients experiencing no relapses or disability progressionFenebrutinib suppressed acute and chronic MRI lesionsFenebrutinib’s safety profile was consistent...
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
27 août 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregiversApproval...
Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak
20 août 2024 08h30 HE
|
F. Hoffmann-La Roche Ltd
Roche is committed to supporting all those working to overcome the mpox outbreak by providing access to high-quality Polymerase Chain Reaction (PCR) testingRoche confirms that its cobas MPXV test, as...
European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)
30 juil. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept, and robust retinal...
Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
29 juil. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances.LumiraDx’s transformative Point of Care solution will complement Roche’s diagnostics...
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Halbjahr 2024 um 5% (CER); starkes Wachstum im zweiten Quartal – Gewinnprognose für das Gesamtjahr erhöht
25 juil. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Konzernverkäufe stiegen im ersten Halbjahr um 5%1 zu konstanten Wechselkursen (CER; stabil in CHF) dank starker Nachfrage sowohl nach Medikamenten als auch nach Diagnostika; ohne COVID-19-Produkte...